Calamos Advisors LLC Makes New Investment in Cerevel Therape

Calamos Advisors LLC purchased a new position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 305,303 shares of the biotechnology company’s stock, valued at approximately $12,945,000. Calamos Advisors LLC owned 0.17% of Cerevel […]

Related Keywords

United States , Canada , N Anthony Coles , John Renger , Tower Research Capital , Centaurus Financial Inc , Jefferies Financial Group , Nasdaq , Royal Bank , Financial Services Group Inc , Ameritas Investment Partners Inc , Jpmorgan Chase Co , Cerevel Therapeutics Holdings Inc , Calamos Advisors , Cerevel Therapeutics Company Profile , Cerevel Therapeutics Holdings , Free Report , Cerevel Therapeutics , Research Capital , Investment Partners , Services Group , Financial Group , Therapeutics Holdings , Directorn Anthony Coles , Visit Holdingschannel , Cerevel Therapeutics Daily , Nasdaq Cere , Racere , Medical , 15677310 , Sec Filings , 13f , Hedge Fund Holdings , Institutional Investor Holdings ,